Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982516 | 1.00 | CTSK (0.51) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL30528465 | 0.90 | VNN1 (0.46) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL17365581 | 0.90 | VNN1 (0.46) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL26293714 | 0.86 | CTSK (0.52) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL1060083 | 0.84 | CTSK (0.48) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL12190794 | 0.84 | CTSK (0.48) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL3484242 | 0.84 | CTSK (0.48) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL1644694 | 0.84 | CTSK (0.50) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL5898498 | 0.81 | CTSK (0.48) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL5898313 | 0.81 | CTSK (0.48) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104557757-A | CETP inhibitors | MERCK & CO INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104447603-A | CETP inhibitors | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| CN-102304096-B | CETP inhibitors | MERCK SHARP & DOHME | 2014-12-03 | — | — | CN | disclosed |
| CN-102311401-B | CETP inhibitors | MERCK & CO INC | 2014-12-03 | — | — | CN | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009102893-A2 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | CTSK 3326/4885CTSS 3537/4885CTSL 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.